Poolbeg Pharma (POLB) has received a fresh vote of confidence from Cavendish after completing its recently announced £3.5 million placing, with the broker reiterating its Buy recommendation and 19p target price. Based on the current share price of 6.1p, Cavendish believes the stock offers about 214% upside, arguing the fundraising significantly improves Poolbeg's position in ongoing partnering discussions while fully funding two key clinical programmes through to completion.
The broker said the capital raise, which included a £250,000 subscription from Executive Chair Cathal Friel, extends Poolbeg's cash runway into the second quarter of 2028. It expects the proceeds to fund both the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept study, reducing financial risk across both programmes while strengthening the company's balance sheet as licensing discussions continue.
Cavendish highlighted the company's growing pipeline momentum following the recent dosing of the first patient in the POLB 001 TOPICAL study. Interim data from the trial remains on track for late summer 2026 and is viewed as a major value inflection point and potential catalyst for commercial partnerships. The broker also expects further progress from the oral GLP-1 obesity programme during the second half of the year.
While updating its financial forecasts to reflect the placing and higher share count, Cavendish left its underlying assumptions unchanged. The broker increased its forecast year-end cash balance to £5.1 million from £1.9 million and reiterated its positive long-term outlook, saying it continues to see multi-billion-dollar potential for POLB 001 alongside significant opportunity for the company's oral GLP-1 programme.
View from Vox
The latest fundraising removes a significant financing overhang and allows investors to focus on upcoming clinical milestones. With interim POLB 001 data expected later this summer and the oral GLP-1 programme advancing, Poolbeg enters a news-rich period that could prove important for both valuation and partnering opportunities. Cavendish's 19p target price suggests the market has yet to fully reflect that potential.